Metropolis Healthcare has announced the launch of its Centre of Genomics, marking a significant step in scaling its long-standing capabilities in advanced genomics, molecular diagnostics, precision medicine, and genomic research. The Centre of Genomics is designed to deliver clinically actionable genomic insights across the care continuum, supporting multiple high-impact clinical specialties.
As part of the Centre’s technology backbone, Metropolis has augmented its existing sequencing infrastructure with the deployment of Illumina’s NovaSeq™ X Series for research purposes. The NovaSeq™ X system features Illumina’s cutting-edge XLEAP-SBS™ chemistry, offering unmatched throughput, accuracy, and sustainability. The NovaSeq™ X Plus can generate more than 20,000 whole genomes per year, more than double the throughput of Illumina’s previous sequencers. Its unprecedented speed, scale, and accuracy push the limits of what is possible in genetic sequencing, enabling users to unlock discoveries and advancements that were previously beyond reach.
Beyond the newly deployed NovaSeq™ X Series, the Centre of Genomics is supported by an existing, multi-platform NGS infrastructure already operational across Metropolis’ key genomics hubs. The Centre of Genomics brings together multidisciplinary teams of molecular pathologists, genomic scientists, researchers, bioinformaticians, and certified genetic counsellors to ensure that complex genomic data is translated into clear, reliable, and clinically meaningful insights for patient care.
Beyond portfolio expansion, the Centre of Genomics is envisioned as a platform for continuous test development, AI-enabled analytics, and deeper digital integration—strengthening reporting quality, operational efficiency, and clinical impact.